Anduril Doubles Valuation to $61 Billion
Summary
The provided content indicates a technical issue preventing access to a Bloomberg.com page, specifically citing a requirement for JavaScript and cookies to be enabled and not blocked. Users encountering this message are advised to review Bloomberg's Terms of Service and Cookie Policy for more information. For further assistance, a support team contact link is provided, along with a unique block reference ID: 28067b33-4fdf-11f1-8a4a-d890e37fabf9. The message also promotes subscribing to Bloomberg.com for global markets news.
Key takeaway
For users experiencing access issues with Bloomberg.com, you should verify your browser settings to ensure JavaScript and cookies are enabled and not blocked. If problems persist, contact their support team, providing the specific block reference ID to expedite troubleshooting and resolution.
Key insights
Access to Bloomberg.com requires enabled JavaScript and cookies, with support available for technical issues.
In practice
- Enable JavaScript and cookies in your browser.
- Review Bloomberg's Terms of Service and Cookie Policy.
Topics
- Anduril
- Company Valuation
- Financial News
- Investment
- Valuation Increase
Best for: Investor, Executive, Entrepreneur
Related on AIssential
Editorial summary, takeaway, and curation by AIssential. Original article published by Bloomberg Technology.